Iomai Corporation Enters Into Agreement With Heska

New Technology Could Mean Needle-Free Vaccines For Pets

Washington, D.C., July 6, 1998 - Iomai Corporation announced today that it has entered into an agreement with Heska Corporation (Nasdaq: HSKA) under which Heska has the exclusive right to evaluate Iomai's proprietary platform technology for "no-needle", painless vaccination for use in companion animals. This technology, known as Transcutaneous Immunization, is under development for human as well as animal application, with Phase I human trials underway. Under the agreement, Iomai will receive an option fee and, if Heska exercises its option to acquire an exclusive license, license fees, milestone payments, research funding and royalties. Additional terms of the agreement were not disclosed.

Iomai's Transcutaneous Immunization technology, originally developed at the Walter Reed Army Institute of Research, is a non-invasive vaccine delivery technology which treats the surface of the skin with common vaccine components to stimulate a highly effective immune response without irritation. Recent reports on the technology have appeared in the journals Nature and Nature Medicine.

"Iomai Corporation is dedicated to improving human and animal health through the practical and effective delivery of a wide range of vaccines using the Transcutaneous Immunization technology," said Dr. Gregory M. Glenn, Scientific Director of Iomai. "We are pleased to welcome Heska to the growing number of commercial partners committed to the fast track development of this transformational immunization technology. Heska, which exhibits the highest standards of scientific excellence, is a valued partner in the commercial development of this technology and will undertake a significant scientific program as Iomai's companion animal partner."

"We are constantly searching for promising technologies that will enable us to create products that excel in safety, efficacy and convenience for companion animals," said Dr. Robert Grieve, Heska's chief scientific officer. "This agreement with Iomai provides Heska with access to exciting proprietary technology that potentially may allow us to offer veterinarians a safe, needle-free alternative for protecting companion animals against disease."

To return to Sylvia's Cyber Kitty Condo just scratch her banner below....